Gsk Plc · LSE:GSK
Gsk — GlaxoSmithKline — Shareholder Meeting (May 2010)
12 slides from Gsk's shareholder meeting presentation, May 6, 2010
Slide 1: Annual General Meeting
Annual General Meeting Thursday 6 May 2010 Andrew Witty Chief Executive Officer
Slide 2: Strategic priorities
Strategic priorities ay
Slide 3: 2009 performance summary
2009 performance summary Results before major restructuring 2009 2008 % Change £m £m CER £ Turnover 28,368 24,352 3 16 EPS 121.2p 104.7p 2 16 Free Cash Flow 5,254 4,679 12
Slide 4: Commitment to grow dividend
Commitment to grow dividend pence 2005 2006 2007 2008 2009
Slide 5: Grow
Slide 6: Investments to grow and diversify GSK's business
Investments to grow and diversify GSK’s business 14 deals completed across the business in 2009 Emerging Markets Pakistan Near EM/AP Algeria East Pharma Vaccines Consumer Walvax AZ Tika Dr Reddy’s (ex-India); Laboratoire Pharmaceutique Algérien (LPA Algeria); Walvax (Priorix in China); Neptunus (flu
Slide 7: Return to sales growth…with a more diversified portfolio
Return to sales growth…with a more diversified portfolio 40% 30% 20% 10% 0% 2007 2008 2009 Proportion of sales from ‘white pill/western markets’ reduced 40% to <30%
Slide 8: Deliver
Slide 9: Pipeline delivers: increasing new product contribution
Pipeline delivers: increasing new product contribution Hiberix Pandemrix US US 2007 2008 2009 Sales from 2007-09 launches; CER growth rates
Slide 10: Simplify
Slide 11: Improving returns in pharmaceutical R&D
Improving returns in pharmaceutical R&D Shift R&D spend Increase Discovery2 Grow biopharm Number of Discovery projects originating from from early to late1 externalisation pipeline 60% 80 20 Number of biopharm projects 70 external sources % R&D late-stage spend 60 15 50 50% 40 10 30 20 5 10 40% 0 0
Slide 12: GlaxoSmithKline
GlaxoSmithKline